Studies on hepatotoxicity and toxicokinetics of colchicine.


Journal

Journal of biochemical and molecular toxicology
ISSN: 1099-0461
Titre abrégé: J Biochem Mol Toxicol
Pays: United States
ID NLM: 9717231

Informations de publication

Date de publication:
Sep 2019
Historique:
received: 17 09 2018
revised: 29 04 2019
accepted: 02 07 2019
pubmed: 25 7 2019
medline: 18 12 2019
entrez: 24 7 2019
Statut: ppublish

Résumé

Colchicine (COL) is an alkaloid existing in plants of Liliaceous colchicum. It has widely been used in the treatments of many diseases, such as gout, Familial Mediterranean Fever, and tumor. However, the adverse effects of COL are an obstacle to its safe use. The present studies explored the role of metabolic demethylation in the development of COL-induced hepatotoxicity. We found that inhibition of CYP3A increased the susceptibility of mice to COL hepatotoxicity, and induction of CYP3A decreased the susceptibility of animals to the hepatotoxicity. The toxicokinetic study demonstrated that pretreatment with ketoconazole caused elevated area under the concentration-time curve of COL. Three demethylation metabolites of COL were found to be less hepatotoxic than the parent compound. It appears that the formation of electrophilic demethylation metabolites was not involved in the development of COL-induced liver injury.

Identifiants

pubmed: 31332882
doi: 10.1002/jbt.22366
doi:

Substances chimiques

Cytochrome P-450 CYP3A EC 1.14.14.1
Ketoconazole R9400W927I
Colchicine SML2Y3J35T

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e22366

Subventions

Organisme : National Natural Science Foundation of China
ID : 81830104
Organisme : National Natural Science Foundation of China
ID : 81773813
Organisme : National Natural Science Foundation of China
ID : 81430086

Informations de copyright

© 2019 Wiley Periodicals, Inc.

Auteurs

Xiucai Guo (X)

Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, China.

Yan Chen (Y)

Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, China.

Qingmei Li (Q)

Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, China.

Xiaojing Yang (X)

Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, China.

Guode Zhao (G)

School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang, China.

Ying Peng (Y)

Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, China.

Jiang Zheng (J)

Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, China.
State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, Guizhou, China.
Key Laboratory of Pharmaceutics of Guizhou Province, Guizhou Medical University, Guiyang, Guizhou, China.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH